What is the recommended management of refractory ascites?

Treatment of Refractory Ascites

The primary management of refractory ascites consists of repeated large-volume paracentesis (LVP) with albumin infusion, with transjugular intrahepatic portosystemic shunt (TIPSS) as the definitive treatment option for appropriate candidates, while all patients should be immediately evaluated for liver transplantation given the poor prognosis (median survival ~6 months). 1

Initial Assessment and Liver Transplant Referral

Once refractory ascites is diagnosed (ascites unresponsive to maximum diuretics: spironolactone 400 mg/day plus furosemide 160 mg/day for at least one week with sodium restriction <90 mmol/day), immediately refer the patient for liver transplant evaluation 2. This is non-negotiable—refractory ascites carries a median survival of approximately 6 months, and transplant is the only curative option.

Diuretic Management After Diagnosis

Discontinue diuretics once refractoriness is confirmed 2. The only exception: if urinary sodium excretion on diuretics exceeds 30 mmol/day, you may continue diuretics if tolerated 2. This is a critical decision point—continuing ineffective diuretics only increases the risk of renal impairment and electrolyte disturbances without benefit.

Primary Treatment: Large-Volume Paracentesis with Albumin

Perform serial LVP as the mainstay of symptomatic management:

• Remove ≥5 liters: Infuse 20% or 25% albumin at 8 g per liter of ascites removed (high-quality evidence, strong recommendation) 1
• For <5 liters removed: Consider albumin at the same dose (8 g/L) in patients with acute-on-chronic liver failure (ACLF) or high risk of post-paracentesis circulatory dysfunction 1
• Ultrasound guidance should be used when available to reduce adverse events 1
• Do NOT routinely check coagulation parameters or transfuse blood products before paracentesis (moderate-quality evidence) 1

The albumin infusion is critical—it prevents post-paracentesis circulatory dysfunction, which can precipitate renal failure and worsen outcomes.

Definitive Treatment: TIPSS

TIPSS should be considered in all patients with refractory ascites (high-quality evidence, strong recommendation) 1. This is the most important intervention that can improve both quality of life and survival beyond repeated paracentesis.

Patient Selection for TIPSS

Exercise caution or avoid TIPSS if the patient has 1:

• Age >70 years
• Serum bilirubin >50 μmol/L (approximately 3 mg/dL)
• Platelet count <75×10⁹/L
• MELD score ≥18
• Current hepatic encephalopathy
• Active infection
• Hepatorenal syndrome

These contraindications reflect patients with insufficient hepatic reserve who are more likely to experience hepatic decompensation or encephalopathy post-TIPSS. The 2021 guidelines provide moderate-quality evidence for these specific cutoffs 1.

Management of Non-Selective Beta-Blockers (NSBBs)

Refractory ascites is NOT a contraindication to NSBBs (moderate-quality evidence, strong recommendation) 1. This represents an important shift from older practice patterns. However:

• Monitor closely for hypotension and renal dysfunction
• Reduce dose or discontinue if the patient develops hypotension or acute/progressive renal dysfunction 1

The controversy around NSBBs in advanced cirrhosis has been clarified—they can be continued but require vigilant monitoring.

Adjunctive Considerations

Midodrine

May be considered on a case-by-case basis in refractory ascites (low-quality evidence, weak recommendation) 1. This alpha-agonist can improve renal perfusion in select patients, but evidence remains limited.

Hyponatremia Management

• Fluid restriction (1-1.5 L/day) only for severe hyponatremia (<125 mmol/L) with clinical hypervolemia 1
• Hypertonic saline (3%) reserved for severely symptomatic acute hyponatremia with slow correction 1

Automated Low-Flow Ascites Pump (Alfapump®)

Consider only in special circumstances with robust clinical governance or research protocols (low-quality evidence, weak recommendation) 1. This is not standard care and should be reserved for patients who are not TIPSS or transplant candidates 3.

Palliative Care

For patients not undergoing liver transplant evaluation, offer palliative care referral (strong recommendation despite weak evidence) 1. Refractory ascites in non-transplant candidates represents end-stage disease, and quality of life becomes the primary focus alongside repeated LVP.

Critical Pitfalls to Avoid

1. Continuing high-dose diuretics after confirming refractoriness—this only causes harm through renal impairment and electrolyte disturbances
2. Delaying transplant referral—the 6-month median survival means every week counts
3. Avoiding TIPSS in appropriate candidates—this is the only intervention besides transplant that improves survival
4. Discontinuing NSBBs reflexively—they can be continued with monitoring unless complications develop
5. Performing paracentesis without albumin—this significantly increases the risk of circulatory dysfunction and renal failure

Treatment Algorithm Summary

1. Confirm refractory ascites diagnosis → Immediately refer for liver transplant evaluation
2. Discontinue diuretics (unless urinary sodium >30 mmol/day)
3. Initiate serial LVP with albumin (8 g/L removed for volumes ≥5 L)
4. Evaluate for TIPSS if no contraindications (age ≤70, bilirubin ≤50 μmol/L, platelets ≥75×10⁹/L, MELD <18, no encephalopathy/infection/HRS)
5. Continue NSBBs with monitoring unless hypotension or renal dysfunction develops
6. Consider palliative care if not a transplant candidate

The evidence strongly supports this stepwise approach, with the 2021 Gut guidelines 1 providing the most recent and comprehensive recommendations, superseding the 2018 EASL guidelines 2 on several key points, particularly regarding NSBBs and TIPSS patient selection.